<code id='C3636BB157'></code><style id='C3636BB157'></style>
    • <acronym id='C3636BB157'></acronym>
      <center id='C3636BB157'><center id='C3636BB157'><tfoot id='C3636BB157'></tfoot></center><abbr id='C3636BB157'><dir id='C3636BB157'><tfoot id='C3636BB157'></tfoot><noframes id='C3636BB157'>

    • <optgroup id='C3636BB157'><strike id='C3636BB157'><sup id='C3636BB157'></sup></strike><code id='C3636BB157'></code></optgroup>
        1. <b id='C3636BB157'><label id='C3636BB157'><select id='C3636BB157'><dt id='C3636BB157'><span id='C3636BB157'></span></dt></select></label></b><u id='C3636BB157'></u>
          <i id='C3636BB157'><strike id='C3636BB157'><tt id='C3636BB157'><pre id='C3636BB157'></pre></tt></strike></i>

          hotspot

          hotspot

          author:fashion    Page View:4
          Cambridge: AbbVie
          The pharma giant AbbVie spent nearly $4 million on lobbying in the first three months of 2022 — nearly a million dollars more than the company has ever spent in a single quarter. Ruby Wallau for STAT

          WASHINGTON — The pharma giant AbbVie spent nearly $4 million on lobbying in the first three months of 2022 alone — more than any other drugmaker spent in the same period, and nearly a million dollars more than the company spent in the same period last year.

          AbbVie was the seventh-highest corporate lobbying spender last quarter, ahead of giants like Lockheed Martin, CVS Health, and, AT&T, federal records show.

          advertisement

          The number is eye-popping even for the pharmaceutical industry, which is known for its omnipresence on Capitol Hill, and its nearly unlimited lobbying budgets.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          FDA panel signals lack of confidence in Amgen cancer drug data
          FDA panel signals lack of confidence in Amgen cancer drug data

          AdobeTheclearanceofafirst-of-its-kindcancertreatmentmadebyAmgenisonshakiergroundfollowingaFoodandDru

          read more
          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more

          Was Amgen transparent enough on FDA's concern on cancer drug?

          MarkJ.Terrill/APAmidthestunningrebukeAmgensufferedatthehandsoftheU.S.FoodandDrugAdministrationthiswe